Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (1-10 of 388) with videos related to

Pageof 39
Sort By:
Future Oncology (London, England)|December 14, 2011
The European Multidisciplinary Cancer Congress (ECCO 16, ESMO 36 and ESTRO 30)Camillo Porta
Expert Review of Anticancer Therapy|December 27, 2005
Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancerCamillo Porta
Therapeutic Advances in Urology|April 18, 2018
Sunitinib in the treatment of renal cell carcinoma: an update on recent evidenceMimma Rizzo, Camillo Porta
World Journal of Hepatology|December 17, 2010
Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenibCamillo Porta, Chiara Paglino
Cancer Treatment Reviews|March 3, 2009
Tolerability of first-line therapy for metastatic renal cell carcinomaCamillo Porta, Cezary Szczylik
Expert Opinion on Pharmacotherapy|January 24, 2012
3rd Pavia international symposium on advanced kidney cancerCamillo Porta, Sergio Bracarda
The Journal of Urology|October 20, 2009
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitorsCamillo Porta, Robert A Figlin
Frontiers in Oncology|May 1, 2014
Targeting PI3K/Akt/mTOR Signaling in CancerCamillo Porta, Chiara Paglino, Alessandra Mosca
Immunotherapy|April 6, 2011
Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximabCamillo Porta, Paolo Pedrazzoli, Chiara Paglino
Seminars in Thrombosis and Hemostasis|January 3, 2006
Autoimmunity in thrombotic thrombocytopenic purpuraCamillo Porta, Roberto Caporali, Carlomaurizio Montecucco
Pageof 39

Showing results (1-10 of 388) with videos related to

Sort By:
Pageof 39
Future Oncology (London, England)|December 14, 2011
The European Multidisciplinary Cancer Congress (ECCO 16, ESMO 36 and ESTRO 30)Camillo Porta
Expert Review of Anticancer Therapy|December 27, 2005
Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancerCamillo Porta
Therapeutic Advances in Urology|April 18, 2018
Sunitinib in the treatment of renal cell carcinoma: an update on recent evidenceMimma Rizzo, Camillo Porta
World Journal of Hepatology|December 17, 2010
Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenibCamillo Porta, Chiara Paglino
Cancer Treatment Reviews|March 3, 2009
Tolerability of first-line therapy for metastatic renal cell carcinomaCamillo Porta, Cezary Szczylik
Expert Opinion on Pharmacotherapy|January 24, 2012
3rd Pavia international symposium on advanced kidney cancerCamillo Porta, Sergio Bracarda
The Journal of Urology|October 20, 2009
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitorsCamillo Porta, Robert A Figlin
Frontiers in Oncology|May 1, 2014
Targeting PI3K/Akt/mTOR Signaling in CancerCamillo Porta, Chiara Paglino, Alessandra Mosca
Immunotherapy|April 6, 2011
Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximabCamillo Porta, Paolo Pedrazzoli, Chiara Paglino
Seminars in Thrombosis and Hemostasis|January 3, 2006
Autoimmunity in thrombotic thrombocytopenic purpuraCamillo Porta, Roberto Caporali, Carlomaurizio Montecucco
Pageof 39